DVAX - ダイナバックス・テクノロジ―ズ （Dynavax Technologies Corporation） ダイナバックス・テクノロジ―ズDVAXのチャート
DVAXの企業情報
| symbol | DVAx |
|---|---|
| 会社名 | Dynavax Technologies Corp （ダイナバックス・テクノロジ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ダイナバクス・テクノロジーズ（Dynavax Technologies Corporation）は臨床段階の免疫療法会社である。同社はトール様受容体（TLR）刺激を通じて身体の本能と適応免疫応答を活用することに集中する。同社の製品候補は複数の癌適応症、B型肝炎の予防ワクチン、および喘息疾患修正療法として開発される。同社の製品はHEPLISAV-B、AZD1419、SD-101、DV281、DV230FとDV1001を含む。HEPLISAV-Bは治験成人のB型肝炎ワクチンである。AZD1419は喘息の治療として開発される。SD-101は癌に対する免疫応答を誘発するように設計される治験用TLR9アゴニストである。DV281は原発性肺腫瘍および肺転移への集中送達のためのTLR9アゴニストである。DV230Fは肝腫瘍の治療に適応する。DV1001は複数悪性腫瘍のTLR7、8アゴニストを標的とする。DV230FとDV1001は開発の前臨床段階である。 ダイナバックス・テクノロジ―ズは米国の臨床検査段階のバイオ医薬品会社。感染症、炎症性疾、自己免疫疾患治療薬の研究、開発に従事。候補製剤にはB型肝炎ワクチン｢ヘプリサブ｣、自己免疫疾患治療用｢DV1179｣、喘息治療用｢AZD1419｣、癌免疫療法｢SD-101｣などがある。 dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b. |
| 本社所在地 | 2929 Seventh Street Suite 100 Berkeley CA 94710-2753 USA |
| 代表者氏名 | Arnold L. Oronsky アーノルドエルオロスキー |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 510-848-5100 |
| 設立年月日 | 35278 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2004年 |
| 従業員数 | 170人 |
| url | www.dynavax.com |
| nasdaq_url | https://www.nasdaq.com/symbol/dvax |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -115.44000 |
| 終値（lastsale） | 11.07 |
| 時価総額（marketcap） | 693154537.02 |
| 時価総額 | 時価総額（百万ドル） 700.66840 |
| 売上高 | 売上高（百万ドル） 1.49300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 584.39640 |
| 当期純利益 | 当期純利益（百万ドル） -127.95100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Dynavax Technologies Corporation revenues increased from $253K to $1.4M. Net loss increased 72% to $78.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $2.3M to $17.5M (expense). |
DVAXのテクニカル分析
DVAXのニュース
Dynavax to Present at the JMP Securities Life Sciences Conference 2023/05/08 20:15:00 PR Newswire
EMERYVILLE, Calif., May 8, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the JMP Securities Life…
Dynavax Technologies: The Covid Lifeline Expires 2023/05/03 19:17:55 Seeking Alpha
Dynavax Technologies reported Q1 earnings after hours on Tuesday. Its HEPLISAV-B franchise continues taking market share. Click for our thoughts on DVAX stock.
Dynavax Technologies (DVAX) Q1 2023 Earnings Call Transcript 2023/05/03 02:00:18 The Motley Fool
DVAX earnings call for the period ending March 31, 2023.
Dynavax Technologies Corporation (DVAX) Q1 2023 Earnings Call Transcript 2023/05/02 23:33:06 Seeking Alpha
Dynavax Technologies Corporation (NASDAQ:NASDAQ:DVAX) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ETCompany ParticipantsPaul Cox - VP of IR and Corporate CommunicationsRyan Spencer…
Dynavax misses on bottom line, but reaffirms 2023 guidance 2023/05/02 21:11:45 Seeking Alpha
Although its Q1 2023 bottom line results came in below expectations, Dynavax Technologies (DVAX) is trading flat in after-hours trading. Read more here.
Dynavax to Present at the JMP Securities Life Sciences Conference 2023/05/08 20:15:00 PR Newswire
EMERYVILLE, Calif., May 8, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the JMP Securities Life…
Dynavax Technologies: The Covid Lifeline Expires 2023/05/03 19:17:55 Seeking Alpha
Dynavax Technologies reported Q1 earnings after hours on Tuesday. Its HEPLISAV-B franchise continues taking market share. Click for our thoughts on DVAX stock.
Dynavax Technologies (DVAX) Q1 2023 Earnings Call Transcript 2023/05/03 02:00:18 The Motley Fool
DVAX earnings call for the period ending March 31, 2023.
Dynavax Technologies Corporation (DVAX) Q1 2023 Earnings Call Transcript 2023/05/02 23:33:06 Seeking Alpha
Dynavax Technologies Corporation (NASDAQ:NASDAQ:DVAX) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ETCompany ParticipantsPaul Cox - VP of IR and Corporate CommunicationsRyan Spencer…
Dynavax misses on bottom line, but reaffirms 2023 guidance 2023/05/02 21:11:45 Seeking Alpha
Although its Q1 2023 bottom line results came in below expectations, Dynavax Technologies (DVAX) is trading flat in after-hours trading. Read more here.
7 Biotech Stocks Sitting in the Sweet Spot 2023/03/24 10:30:57 InvestorPlace
Biotech stocks aren’t for everyone. They require some additional research and as an investor you have to be comfortable having product pipelines with a long pathway to market. Biotech companies can pour millions into research and development and have nothing to show with it. Biotech companies are on the leading edge of scientific innovation, and they bring in massive profits if they develop a drug that’s deemed to be safe and marketable. Small biotech companies that have potentially attractive drugs in their pipelines can draw the attention of larger pharmaceutical companies. That could lead to buyouts that could be extremely profitable for investors who get in on the ground floor. So, if you’ve got a decent risk tolerance, biotech stocks could be really attractive. I’ve used the Portfolio Grader to pick out several here that are worthy of further scrutiny. DRRX Durect $4.55 DVAX Dynavax Technologies $9.65 EDAP EDAP TMS $11.09 ELVN Enliven Therapeutics $22.68 FDMT 4D Molecular Therapeutics $17.04 FENC Fennec Pharmaceuticals $7.52 GERN Geron $2.22 Durect (DRRX) Source: shutterstock.com/Romix Image Durect (NASDAQ: DRRX ) is one of my favorite cheap stocks to buy right now.
The Top 7 Growth Stocks in Biotech 2023/03/03 23:57:06 InvestorPlace
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics. The rewards for bringing such products to market are significant. But biotech growth stocks also generally carry much higher risk than the average stock. Additionally, companies in the biotech industry face regulatory approval processes and intellectual property disputes that can result in significant near-term volatility. Nevertheless, the potential for substantial returns makes biotech stocks perpetually attractive. Identifying companies with the best chances of developing breakthrough drugs or therapies is paramount to success. Let’s take a look at seven companies that I think fit that profile. ITOS iTeos Therapeutics $17.30 VIR Vir Biotechnology $22.84 BEAM Beam Therapeutics $39.10 KNSA Kiniksa Pharmaceuticals $12.28 DVAX Dynavax Technologies $10.44 CMRX Chimerix $1.63 APVO Aptevo Therapeutics $2.15 iTeos Therapeutics (ITOS) Source: motorolka / Shutterstock.com Stocks like iTeos Therapeutics (NASDAQ: ITOS ) are the kind of equity biotech investors ought to be looking for.
Dynavax to Present at the Cowen 43rd Annual Health Care Conference 2023/03/01 21:15:00 Investors Dynavax
EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Kelly MacDonald , Chief Financial Officer, will participate in a fireside chat